Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB2MKU)

• Drug Name: CIGB-128 Drug Info
• Synonyms: HeberPAG; IFN alpha2b + IFN gamma (injectable, skin cancer), CIGB

Indication

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMB2MKU

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon-alpha 2 (IFNA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Peginterferon alfa-2b	DMAP58Y	Hepatitis C virus infection	1E51.1	Approved	[3]
Interferon Alfa-2b	DMWCQP4	Melanoma	2C30	Approved	[3]
Peginterferon alfa-2a	DMJI3BA	Chronic hepatitis B virus infection		Approved	[3]
Albinterferon alfa-2b	DMK0QW6	Hepatitis C virus infection	1E51.1	Phase 3	[4]
Interferon alpha 2a	DMOTH6V	Hepatitis C virus infection	1E51.1	Phase 3	[5]
Hebergel	DMQTLVB	Virus infection	1A24-1D9Z	Phase 3	[6]
P-1101	DM7WYXJ	Essential thrombocythemia	3B63.1Z	Phase 3	[7]
Interferon alpha-2b	DMVACTU	Hepatitis C virus infection	1E51.1	Phase 2	[8]
Novaferon	DMEHOI1	Colorectal cancer	2B91.Z	Phase 2	[9]
Instiladrin	DMNKAFQ	Bladder cancer	2C94	Phase 2	[10]

Drug(s) Targeting Interferon-gamma (IFNG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Emapalumab	DMZG5WL	Primary haemophagocytic lymphohistiocytosis	4A01.23	Approved	[11]
Fumaric acid	DMP83UZ	Multiple sclerosis	8A40	Phase 3	[12]
VIR-201	DMAMIU4	Human immunodeficiency virus infection	1C62	Phase 1/2	[13]
AMG 811	DMEIMBP	Discoid lupus erythematosus	EB51.0	Phase 1	[14]
CRx-191	DMB9QSJ	Psoriatic disorder	EA90	Discontinued in Phase 2	[15]
TAK-603	DMN1YHP	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[16]
Fontolizumab	DMEH6LV	Inflammatory bowel disease	DD72	Discontinued in Phase 2	[17]
TG-1042	DMS4BUK	B-cell lymphoma	2A86	Discontinued in Phase 2	[18]
VPM-4-001	DMZHAVG	Prostate cancer	2C82.0	Preclinical	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon-alpha 2 (IFNA2)	TTSIUJ9	IFNA2_HUMAN	Modulator	[2]
Interferon-gamma (IFNG)	TT93WF5	IFNG_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037683)
• [2] Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002.
• [5] Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60.
• [6] Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7.
• [7] Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8.
• [8] Clinical pipeline report, company report or official report of Avarx.
• [9] Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8.
• [10] ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health.
• [11] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [12] Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77.
• [13] EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents.
• [14] Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53.
• [15] CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008.
• [16] T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11.
• [17] Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59.
• [18] Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8.
• [19] BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5.